Dr. Thérèse Croughs has more than 20 years of experience in clinical development and regulatory affairs. She has worked in companies of varying sizes and clinical stages of development in the pharmaceutical and biotech industries in Europe, North America and Asia.
Thérèse Croughs began her career in the pharmaceutical industry at Bayer, where she worked on protocol definition and the conduct of several clinical trials, as well as the registration of several products, including r-FVIII in hemophilia. A. After 10 years at Bayer, Thérèse joined the Novo Nordisk team as International Medical Advisor for the clinical development in Europe of r-FVIIa for the treatment of severe bleeds. Thérèse Croughs continued her career at BioAlliance Pharma, where she held the position of Director of the Adhesive Technology and New Business Unit and Director of European Regulatory Affairs. More recently and for more than 6 years, Thérèse Croughs was the Medical Director of Cytheris where she was in charge of regulatory strategy and international development of the IL-7 immunotherapy program (r-hIL-7, a factor growth of the immune system). Thérèse Croughs is a graduate of the Faculty of Medicine of the Catholic University of Louvain – Brussels, Belgium. Since 2015, she is Chef Medical Officer for NEOVACS.